Primary%20biliary%20cholangitis News

News

UDCA-induced GLOBE score changes tied to survival in primary biliary cholangitis

20230804110000

In patients with primary biliary cholangitis (PBC), changes in the GLOBE score (ΔGLOBE) brought about by treatment with ursodeoxycholic acid (UDCA) are predictive of liver transplantation (LT)-free survival, reports a study.

LSM improves prediction of cholangitis outcomes

20221128130000

Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) is independently associated with primary biliary cholangitis (PBC) outcomes, a study has shown.

Ursodeoxycholic acid response tied to lower mortality in PBC with cirrhosis

20211010110000

Ursodeoxycholic acid (UDCA) response contributes to a decrease in decompensation, all-cause, and liver-related death or transplantation in predominantly male patients with cirrhosis, reveals a study, noting the highest benefit in those with portal hypertension.

Obeticholic acid safe, effective in select patients with primary biliary cholangitis

20210130140000

Obeticholic acid is beneficial to primary biliary cholangitis patients with suboptimal response to ursodeoxycholic acid, significantly improving prognostic score with good tolerability, according to the results of an open-label study.

UDCA for primary sclerosing cholangitis may lower biliary tract cancer risk

Roshini Claire Anthony, 20201222180001

Patients with primary sclerosing cholangitis (PSC) who are treated with ursodeoxycholic acid (UDCA) may have a lower risk of liver transplantation, all-cause death, or biliary tract cancer, according to a study from Japan.

Proton pump inhibitors implicated in cholangitis

20190926180000

Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Product Highlight - Ravida

13 Sep 2022

Ravidasvir 200 mg tab

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).